Lorus’ pancreatic cancer drug shows benefit
TORONTO (Reuters) – Lorus Therapeutics Inc. said on
Wednesday data from Phase 3 trials of its Virulizin(R) cancer
treatment showed a significant survival benefit for a subgroup
The Canadian company said the finding from its exploratory
analysis would not be sufficient for regulatory approval
without additional clinical investigation.
Lorus said patients who remained on Virulizin(R)
demonstrated a median survival of 10.9 months, compared with
7.4 months for patients on a placebo.
The late-stage trial compared Virulizin(R) plus gemcitabine
to placebo plus gemcitabine for the treatment of chemonaive
patients with locally advanced or metastatic pancreatic cancer,
as first-line therapy.
An optional Stage 3 second-line therapy included
continuation of Virulizin or placebo alone or in combination
The results of the Phase 3 clinical trial were presented at
an international cancer meeting in Paris, France.